AlphAIalphai — Financial news for AI agents
fool.comJUL 308 min read$GEHC

GE HealthCare (GEHC) Q2 2026 Earnings Call Transcript

Wednesday, July 29, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Investor Relations Officer - Carolynne Borders President and Chief Executive Officer - Peter Arduini Vice President and Chief Financial Officer - Jay Saccaro Controller and Chief Accounting Officer - George Newcomb TAKEAWAYS Total Revenue -- $5.3 billion, representing 5.7% growth compared to the prior year.

Original reporting
fool.com
Published Jul 30, 2026, 10:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 11:54 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
GE HealthCare (GEHC) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$GEHCNeutralMed
01

Why it matters

Demand indicators (organic orders +11.1%, book-to-bill 1.15x, backlog up to $23.9B) support revenue visibility, but PCS EBIT turned negative (-$26M) and management is conducting a strategic review that could introduce execution risk or restructuring costs.

02

Market read

Traders can update models using the explicit guidance ranges (EPS, EBIT margin, organic revenue, and FCF) and the stated PCS strategic review, which can affect risk premium and timing of earnings recovery.

03

What to watch

Free cash flow was relatively low in the quarter ($68M) despite tariff refunds, suggesting working-capital and capex timing could be a recurring swing factor into 2H 2026.

Relevance 8/10Novelty 7/10Timing: post-call, for positioning ahead of next earnings/quarterly updates

Background

GE HealthCare’s Q2 2026 earnings call covered segment performance (AIS, PDx, PCS), margin drivers (inflationary inputs), and full-year 2026 guidance plus strategic options for PCS.

Company-level read

Ticker impact

$GEHCNeutralMedium confidence
Context

GE HealthCare reported Q2 2026 results and reiterated full-year 2026 guidance, including EPS $4.80 to $5.00 and FCF guidance of about $1.6B.

Expected impact

Near-term trading likely hinges on how investors discount PCS margin weakness versus AIS/PDx strength and the credibility of the PCS strategic review.

Evidence & confidence

The article provides multiple decision-grade datapoints: book-to-bill 1.15x, backlog $23.9B, adjusted EBIT margin 14.2% with PCS underperformance, and explicit full-year guidance ranges plus a stated review of PCS options.

Market effects

Sector

Signals continued demand strength in contrast media and imaging systems, while medical device monitoring/anesthesia faces supply-chain and fulfillment headwinds.

Regional

Europe focus via expected CE marking for Photonova Spectra in 2H 2026 could support regional imaging demand expectations.

Global

Contrast media supply tightness and expected market doubling over the decade may influence broader imaging and radiopharma supply-chain sentiment.

Counterpoint

What could challenge this read

The headline strength in orders and backlog may not translate into near-term earnings quality if PCS conversion and component shortages persist longer than management expects.

Key entities

  • company
    GE HealthCare Technologies Inc.

    Reported Q2 2026 results, reiterated full-year 2026 guidance, and disclosed a strategic review of the Patient Care Solutions segment.

  • executive
    Peter Arduini

    CEO who discussed PCS performance challenges and technology modernization agreements with Catholic Health.

  • executive
    Jay Saccaro

    CFO who cited inflationary headwinds and provided margin and demand commentary for contrast media.

Read at source← All news

Related articles

AUG 5
$SHOPMed

Shopify surges, AMD slides premarket as earnings disappoint

U.S. stock index futures rose slightly as Strait of Hormuz reopening talks were seen as progressing. Shopify shares jumped 26% after Q2 revenue of $3.58B beat $3.45B, with EPS $0.42 and gross merchandise volume up 32%. AMD shares fell 8.8% on a weaker revenue outlook. SpaceX said it will use Nvidia chips, pressuring AMD and wireless peers.

investing.com6 min
AUG 5
$GEHCMed

5 Insightful Analyst Questions From GE HealthCare’s Q2 Earnings Call

GE HealthCare reported Q2 revenue of $5.30B vs $5.27B estimates and adjusted EPS of $1.13 vs $1.04, with organic revenue up 3.5% and full-year adjusted EPS guidance reiterated at $4.90 (midpoint). Management cited strong orders growth, including Pharmaceutical Diagnostics and Advanced Imaging. Analysts asked about orders sustainability, Flyrcado ramp, PCS stabilization, inflation, and China dynamics.

financialcontent.com6 min
JUL 31
$GEHCMed

GE HealthCare Technologies Inc. Q2 2026 Earnings Call Summary

Strategic Performance Drivers Achieved record organic orders growth of 11.1% and a record backlog of $23.9 billion, driven by healthy end-market demand and successful commercial realignment. Performance was led by Pharmaceutical Diagnostics (PDx) and Advanced Imaging Solutions (AIS), which combined for 6.5% growth and 100 basis points of margin expansion.

yahoo.com6 min
JUL 31
$MSFTMed

Stocks Tumble as Chipmakers Plunge, Oil Spikes

US MBA mortgage applications fell -6.4% in the week ended July 24, with the purchase mortgage sub-index down -3.6% and the refinancing mortgage sub-index down -9.9%. The average 30-year fixed rate mortgage rose +7 bp to an 11.5-month high of 6.76% from 6.69% the prior week. The outlook for strong Q2 earnings, which continue this week, is a bullish factor for stocks.

yahoo.com7 min
JUL 30
$GEHCMed

GE HealthCare Technologies Q2 Earnings Call Highlights

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk's Play Adjusted EBIT was $750 million, including $23 million of recognized refunds related to tariffs incurred during the first quarter. Adjusted EBIT margin was 14.2%, down 40 basis points year over year. Adjusted earnings per share rose 6.6% to $1.13, including a $0.04 benefit from tariff refunds and a $0.02 benefit from a lower tax rate compared with the prior year.

yahoo.com6 min
JUL 30
$GEHCMed

GE HealthCare’s ‘Record’ Quarter Amid CFO Transition

GE HealthCare reported Q2 2026 revenue of $5.3bn, up 5.7% year over year, with adjusted EPS up 6.6% and order growth up a record 11%, according to the company. Imaging revenue rose to $3.7bn. Pharmaceutical Diagnostics revenue grew 15.6%, while Patient Care Solutions revenue fell 13.3%. CFO Jay Saccaro steps down Aug. 14, 2026; George Newcomb becomes interim CFO.

healthcare-digital.com6 min